The pan-CLK inhibitor SM08502 displays anti-tumor activity in gastrointestinal cancer models [8], while the potent CLK2 inhibitor T-025 demonstrates anti-tumor efficacy in an allograft model of MYC-driven breast cancer [9]. The gene discussed is CLK1; the disease is neoplasm.